An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam

Epilepsy and Behavior

Volumn 52, Issue , 2015, Pages 165-168

  Yates, Stephen L ^a   Fakhoury, Toufic ^b   Liang, Wei ^a   Eckhardt, Klaus ^a   Borghs, Simon ^a   D'Souza, Joseph ^a  

^a UCB PHARMA   (Belgium)

^b Kentucky One Health   (United States)

Author keywords

Behavioral adverse event; Brivaracetam; Epilepsy; Levetiracetam; Quality of life

Indexed keywords

BRIVARACETAM; ETIRACETAM; 2 PYRROLIDONE DERIVATIVE; 2-(2-OXO-4-PROPYLPYRROLIDIN-1-YL)BUTANAMIDE; ANTICONVULSIVE AGENT; PIRACETAM;

ADULT; ADVERSE DRUG REACTION; ARTICLE; BACKACHE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPILEPSY; EXPLORATORY RESEARCH; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; MALE; MULTICENTER STUDY; OPEN STUDY; PATIENT WEIGHTED QUALITY OF LIFE IN EPILEPSY INVENTORY FORM 31; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RHINOPHARYNGITIS; SINGLE BLIND PROCEDURE; SUICIDAL IDEATION; SUICIDE ATTEMPT; TREMOR; ADOLESCENT; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; MENTAL DISEASE; MIDDLE AGED; PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTICONVULSANTS; EPILEPSY; FEMALE; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; PIRACETAM; PROSPECTIVE STUDIES; PYRROLIDINONES; QUALITY OF LIFE; SUICIDAL IDEATION; SUICIDE, ATTEMPTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84942743446     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2015.09.005     Document Type: Article

References (17)

1. Chung S., Wang N., Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure 2007, 16:296-304.
2. Harden C. Safety profile of levetiracetam. Epilepsia 2001, 42(Suppl. 4):36-39.
3. Keppra® (levetiracetam tablets and oral solution): US prescribing information 2015, UCB Pharma, http://www.ucb.com/_up/ucb_com_products/documents/Keppra_IR_Current_COL_%2003_2015.pdf [Accessed 17th July 2015].
4. French J., Edrich P., Cramer J.A. A systematic review of the safety profile of levetiracetam: a new antiepileptic drug. Epilepsy Res 2001, 47:77-90.
5. Werhahn K.J., Trinka E., Dobesberger J., Unterberger I., Baum P., Deckert-Schmitz M., et al. A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsia 2015, 56:450-459.
6. Gillard M., Fuks B., Leclercq K., Matagne A. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol 2011, 664:36-44.
7. Rigo J.M., Nguyen L., Hans G., Belachew S., Moonen G., Matagne A., et al. UCB 34714: effect on inhibitory and excitatory neurotransmission. Epilepsia 2004, 45(Suppl. 3):54.
8. Carunchio I., Pieri M., Ciotti M.T., Albo F., Zona C. Modulation of AMPA receptors in cultured cortical neurons induced by the antiepileptic drug levetiracetam. Epilepsia 2007, 48:654-662.
9. Biton V., Berkovic S.F., Abou-Khalil B., Sperling M.R., Johnson M.E., Lu S. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia 2014, 55:57-66.
10. Ryvlin P., Werhahn K.J., Blaszczyk B., Johnson M.E., Lu S. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia 2014, 55:47-56.
11. Kwan P., Trinka E., van Paesschen W., Rektor I., Johnson M.E., Lu S. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia 2014, 55:38-46.
12. Klein P., Schiemann J., Sperling M., Whitesides J., Liang W., Stalvey T. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of brivaracetam in adult patients with partial onset seizures. Epilepsy Currents 2015, 15:379. Abstract 2.417.
13. International League Against Epilepsy Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia 1989, 30:389-399.
14. Chung S.S., Fakhoury T.A., Hogan R.E., Nagaraddi V.N., Blatt I., Lawson B., et al. Once-daily USL255 as adjunctive treatment of partial-onset seizures: randomized phase III study. Epilepsia 2014, 55:1077-1087.
15. Tzvetanov P., Waldman Zadeh W., Escartin A., Byrnes W., Tennigkeit F., et al. Safety and effectiveness of lacosamide as a first add-on (FAO) or later add-on (LAO) treatment of partial-onset seizures (POS) in adults: an open-label trial. Neurology 2015, 84(Suppl. 14):4.262.
16. Hufnagel A., Ben-Menachem E., Gabbai A.A., Falcão A., Almeida L., Soares-da-Silva P. Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: results of a 1-year open-label extension study. Epilepsy Res 2013, 103:262-269.
17. Cramer J., Borghs S., De Backer M., Doty P. Improved seizure severity, health-related quality of life and health status reported by patients during long-term treatment with lacosamide: analysis of pooled open-label data. Neurology 2012, 78. (Meeting abstracts 1):PD3.008.